Skip to Content

Join the 'Copaxone' group to help and get support from people like you.

Copaxone News

FDA Approves Glatopa (glatiramer acetate) as the First Generic Competitor to Copaxone

Posted 23 Apr 2015 by Drugs.com

Holzkirchen, Germany, April 16, 2015 - Sandoz, a Novartis company, today announced the US approval of Glatopa, the first generic version of Teva's Copaxone (glatiramer acetate injection) 20 mg/ml one-time-daily multiple sclerosis therapy. "Sandoz, together with Momenta, is proud to be the first company to receive FDA approval for a substitutable generic version of this important therapy," said Peter Goldschmidt, President of Sandoz US. "The approval of Glatopa reinforces Sandoz leadership in complex, differentiated generic products and further demonstrates our commitment to offer patients and payors a full range of therapeutic options." MS is a debilitating disease affecting about half a million individuals in the US alone; only half of those diagnosed are currently treated. Glatopa, developed in collaboration with Momenta and produced entirely in the US, is indicated for the ... Read more

Related support groups: Multiple Sclerosis, Copaxone, Glatiramer

Generic Copaxone Approved for Multiple Sclerosis

Posted 16 Apr 2015 by Drugs.com

THURSDAY, April 16, 2015 – The first U.S. generic version of Copaxone (glatiramer acetate injection) has been approved by the Food and Drug Administration to treat multiple sclerosis (MS). The brand-name drug is produced by Israel-based Teva Pharmaceuticals. It's approved to treat MS, a chronic central nervous system disease caused by an overly aggressive immune system that turns on the body itself. Typical symptoms include muscle weakness, coordination problems and disability. First symptoms usually begin between ages 20 and 40. License to produce the generic equivalent of Copaxone was issued to the Swiss-based drugmaker Sandoz, the FDA said Thursday in a news release. The most common side effects of Copaxone include injection-site redness and pain, flushing, rash, shortness of breath and chest pain. The FDA issued a reminder that generic medications are chemically equivalent to ... Read more

Related support groups: Multiple Sclerosis, Copaxone, Glatiramer

Teva Announces U.S. FDA Approval of Three-Times-a-Week Copaxone (glatiramer acetate injection) 40mg/mL

Posted 29 Jan 2014 by Drugs.com

JERUSALEM--(BUSINESS WIRE)--Jan. 28, 2014-- Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental new drug application (sNDA) for three-times-a-week Copaxone 40mg/mL, a new dose of Copaxone. This new formulation will allow for a less frequent dosing regimen administered subcutaneously for patients with relapsing forms of multiple sclerosis (MS). In addition to the newly approved dose, daily Copaxone 20 mg/mL will continue to be available. The daily subcutaneous injection was approved in 1996. “The availability of three-times-a-week Copaxone 40 mg/mL is a significant advancement for patients as they now have the option of effective and safe treatment with Copaxone, while reducing the number of injections by 60 percent,” said Omar Khan, M.D., Professor of Neurology and Chair of the Department of Neuro ... Read more

Related support groups: Multiple Sclerosis, Copaxone, Glatiramer

Neurology Group Lists Procedures That May Be Unneeded

Posted 8 Mar 2013 by Drugs.com

FRIDAY, March 8 – Five tests, procedures and treatments that neurologists and their patients should question are outlined in a list released by the American Academy of Neurology (AAN) as part of the Choosing Wisely campaign. "With one in six people affected by a brain disease, such as headache, multiple sclerosis and stroke, our goal is to have patients discuss our Choosing Wisely recommendations regarding medical procedures, therapies, and tests with their neurologists," AAN president Dr. Bruce Sigsbee said in an academy news release. The American Board of Internal Medicine Foundation-led Choosing Wisely campaign involves about 35 medical specialty groups and is intended to encourage patients and doctors to discuss appropriate care while avoiding unnecessary tests and treatments. The AAN is one of 17 medical societies that recently released advice lists. Here are the AAN's five ... Read more

Related support groups: Suboxone, Headache, Oxycodone, Migraine, Hydrocodone, Methadone, OxyContin, Vicodin, Norco, Fentanyl, Morphine, Codeine, Lortab, Opana, Subutex, Multiple Sclerosis, Ischemic Stroke, Dilaudid, Opana ER, Roxicodone

Common Asthma Drug Could Speed MS Treatment

Posted 13 Sep 2010 by Drugs.com

MONDAY, Sept. 13 – A common asthma drug might accelerate the benefits of treatment for multiple sclerosis when combined with standard medicine, new research suggests. The authors of this small and preliminary study showed that albuterol, prescribed for a variety of respiratory illnesses, enhances the effects of glatiramer acetate, a drug already prescribed for MS patients. Because albuterol is known to reduce a substance in the body connected to the onset of MS, doctors at Harvard looked at using the drug as an add-on treatment. Study author Dr. Samia J. Khoury said the study was designed to see if the drug helped reduce symptoms of the inflammatory disease. "Albuterol causes the [immune system] cells to change the type of interleukin they produce to one that is beneficial in MS," said Khoury, a professor of neurology at Harvard Medical School and Brigham and Women's Hospital in ... Read more

Related support groups: Multiple Sclerosis, Albuterol, Ventolin, Copaxone, ProAir HFA, Proventil, Ventolin HFA, Proventil HFA, Glatiramer, Volmax, Respirol, Airet, Vospire ER, AccuNeb

Ask a Question

Further Information

Related Condition Support Groups

Multiple Sclerosis

Copaxone Patient Information at Drugs.com